Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.

Reis B, Jukofsky L, Chen G, Martinelli G, Zhong H, So WV, Dickinson MJ, Drummond M, Assouline S, Hashemyan M, Theron M, Blotner S, Lee JH, Kasner M, Yoon SS, Rueger R, Seiter K, Middleton SA, Kelly KR, Vey N, Yee K, Nichols G, Chen LC, Pierceall WE.

Haematologica. 2016 May;101(5):e185-8. doi: 10.3324/haematol.2015.139717. Epub 2016 Feb 11. No abstract available.

2.

Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs.

Ishizawa J, Kojima K, McQueen T, Ruvolo V, Chachad D, Nogueras-Gonzalez GM, Huang X, Pierceall WE, Dettman EJ, Cardone MH, Shacham S, Konopleva M, Andreeff M.

PLoS One. 2015 Sep 16;10(9):e0138377. doi: 10.1371/journal.pone.0138377. eCollection 2015.

3.

MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia.

Zhong H, Chen G, Jukofsky L, Geho D, Han SW, Birzele F, Bader S, Himmelein L, Cai J, Albertyn Z, Rothe M, Essioux L, Burtscher H, Middleton SA, Rueger R, Chen LC, Dangl M, Nichols G, Pierceall WE.

Br J Haematol. 2015 Nov;171(3):432-5. doi: 10.1111/bjh.13411. Epub 2015 Apr 8. No abstract available.

4.

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).

Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA.

Am J Hematol. 2015 Apr;90(4):327-33. doi: 10.1002/ajh.23946. Epub 2015 Feb 25.

5.

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.

Pierceall WE, Warner SL, Lena RJ, Doykan C, Blake N, Elashoff M, Hoff DV, Bearss DJ, Cardone MH, Andritsos L, Byrd JC, Lanasa MC, Grever MR, Johnson AJ.

Leukemia. 2014 Nov;28(11):2251-4. doi: 10.1038/leu.2014.206. Epub 2014 Jul 3. No abstract available.

6.

Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.

Pierceall WE, Lena RJ, Medeiros BC, Blake N, Doykan C, Elashoff M, Cardone MH, Walter RB.

Leuk Res. 2014 May;38(5):564-8. doi: 10.1016/j.leukres.2014.02.007. Epub 2014 Feb 28.

7.

Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.

Whitsett TG, Mathews IT, Cardone MH, Lena RJ, Pierceall WE, Bittner M, Sima C, LoBello J, Weiss GJ, Tran NL.

Mol Cancer Res. 2014 Apr;12(4):550-9. doi: 10.1158/1541-7786.MCR-13-0458. Epub 2014 Jan 27.

8.

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R.

Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23.

9.

BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.

Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, Elashoff M, Konopleva M, Cardone MH, Andreeff M.

Mol Cancer Ther. 2013 Dec;12(12):2940-9. doi: 10.1158/1535-7163.MCT-13-0692. Epub 2013 Oct 3.

10.

Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.

Richard DJ, Lena R, Bannister T, Blake N, Pierceall WE, Carlson NE, Keller CE, Koenig M, He Y, Minond D, Mishra J, Cameron M, Spicer T, Hodder P, Cardone MH.

Bioorg Med Chem. 2013 Nov 1;21(21):6642-9. doi: 10.1016/j.bmc.2013.08.017. Epub 2013 Aug 15.

11.

Microfluidics and circulating tumor cells.

Dong Y, Skelley AM, Merdek KD, Sprott KM, Jiang C, Pierceall WE, Lin J, Stocum M, Carney WP, Smirnov DA.

J Mol Diagn. 2013 Mar;15(2):149-57. doi: 10.1016/j.jmoldx.2012.09.004. Epub 2012 Dec 22. Review.

12.

Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.

Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, Filipits M, Chen Y, Kutok JL, Weaver DT, Ward BE, Soria JC.

Ann Oncol. 2012 Sep;23(9):2245-52. doi: 10.1093/annonc/mdr624. Epub 2012 Jan 23.

PMID:
22269178
13.

Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.

Pierceall WE, Sprott KM, Heikkinen T, Heikkila P, Alaparthi L, Aittomaki K, Al-Adhami M, Villegas-Bergazzi V, Meyer JL, Kutok JL, Bartkova J, Bartek J, Nevanlinna H, Weaver DT, Blomqvist C.

Hum Pathol. 2012 Sep;43(9):1363-75. doi: 10.1016/j.humpath.2011.08.018. Epub 2011 Dec 26.

PMID:
22204715
14.

Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic response diagnostics.

Pierceall WE, Wolfe M, Suschak J, Chang H, Chen Y, Sprott KM, Kutok JL, Quan S, Weaver DT, Ward BE.

Anal Cell Pathol (Amst). 2011;34(3):159-68. doi: 10.3233/ACP-2011-014.

15.

Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.

Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff D, Kawabe T, Sharma S.

Clin Cancer Res. 2011 May 15;17(10):3431-42. doi: 10.1158/1078-0432.CCR-10-2345. Epub 2011 Jan 10.

16.

A phthalide with in vitro growth inhibitory activity from an oidiodendron strain.

Mullady EL, Millett WP, Yoo HD, Weiskopf AS, Chen J, Ditullio D, Knight-Connoni V, Hughes DE, Pierceall WE.

J Nat Prod. 2004 Dec;67(12):2086-9.

PMID:
15620258
17.

Affinity capillary electrophoresis for the screening of novel antimicrobial targets.

Lewis LM, Engle LJ, Pierceall WE, Hughes DE, Shaw KJ.

J Biomol Screen. 2004 Jun;9(4):303-8.

PMID:
15191647
18.

Affinity capillary electrophoresis analyses of protein-protein interactions in target-directed drug discovery.

Pierceall WE, Zhang L, Hughes DE.

Methods Mol Biol. 2004;261:187-98. Review.

PMID:
15064459
19.

Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.

Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP.

Gastroenterology. 2000 Nov;119(5):1219-27.

PMID:
11054379
20.

E75 expression in mosquito ovary and fat body suggests reiterative use of ecdysone-regulated hierarchies in development and reproduction.

Pierceall WE, Li C, Biran A, Miura K, Raikhel AS, Segraves WA.

Mol Cell Endocrinol. 1999 Apr 25;150(1-2):73-89.

PMID:
10411302
21.

Loss of DCC expression in neuroblastoma is associated with disease dissemination.

Reale MA, Reyes-Mugica M, Pierceall WE, Rubinstein MC, Hedrick L, Cohn SL, Nakagawara A, Brodeur GM, Fearon ER.

Clin Cancer Res. 1996 Jul;2(7):1097-102.

22.

Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines.

Pierceall WE, Woodard AS, Morrow JS, Rimm D, Fearon ER.

Oncogene. 1995 Oct 5;11(7):1319-26.

PMID:
7478552
24.

Expression of a homologue of the deleted in colorectal cancer (DCC) gene in the nervous system of developing Xenopus embryos.

Pierceall WE, Reale MA, Candia AF, Wright CV, Cho KR, Fearon ER.

Dev Biol. 1994 Dec;166(2):654-65.

PMID:
7813784
25.

NIH3T3 cells expressing the deleted in colorectal cancer tumor suppressor gene product stimulate neurite outgrowth in rat PC12 pheochromocytoma cells.

Pierceall WE, Cho KR, Getzenberg RH, Reale MA, Hedrick L, Vogelstein B, Fearon ER.

J Cell Biol. 1994 Mar;124(6):1017-27.

26.

Studies of the deleted in colorectal cancer gene in normal and neoplastic tissues.

Fearon ER, Ekstrand BC, Hu G, Pierceall WE, Reale MA, Bigner SH.

Cold Spring Harb Symp Quant Biol. 1994;59:637-43.

PMID:
7587124
27.

High frequency of p53 mutations in ultraviolet radiation-induced murine skin tumors: evidence for strand bias and tumor heterogeneity.

Kanjilal S, Pierceall WE, Cummings KK, Kripke ML, Ananthaswamy HN.

Cancer Res. 1993 Jul 1;53(13):2961-4.

28.

N-ras mutation in ultraviolet radiation-induced murine skin cancers.

Pierceall WE, Kripke ML, Ananthaswamy HN.

Cancer Res. 1992 Jul 15;52(14):3946-51.

29.

Molecular alterations in human skin tumors.

Ananthaswamy HN, Pierceall WE.

Prog Clin Biol Res. 1992;376:61-84. Review.

PMID:
1528930
30.
31.

Presence of human papilloma virus type 16 DNA sequences in human nonmelanoma skin cancers.

Pierceall WE, Goldberg LH, Ananthaswamy HN.

J Invest Dermatol. 1991 Nov;97(5):880-4.

32.

Ras gene mutation and amplification in human nonmelanoma skin cancers.

Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN.

Mol Carcinog. 1991;4(3):196-202.

PMID:
2064725
33.

Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas.

Pierceall WE, Mukhopadhyay T, Goldberg LH, Ananthaswamy HN.

Mol Carcinog. 1991;4(6):445-9.

PMID:
1793482
34.

Molecular mechanisms of ultraviolet radiation carcinogenesis.

Ananthaswamy HN, Pierceall WE.

Photochem Photobiol. 1990 Dec;52(6):1119-36. Review.

PMID:
2087500

Supplemental Content

Loading ...
Support Center